Obesity Management

A review of 22 novel drugs approved by the US Food and Drug Administration during the first half of 2026, with links to coverage from MJH Life Sciences publications.

Catch up on major trial results, groundbreaking FDA decisions, and key clinician insights from major endocrinology conferences.

Leiter discusses the growth of incretin-based therapies through all aspects of the cardio-kidney-metabolic syndrome space.

Stay updated with the latest healthcare breakthroughs, including phase 3 data, new clinical findings, and regulatory updates.

Corxel reported CX11 met phase 2 endpoints in adults with obesity or overweight, with up to 11.5% weight loss at 36 weeks.

A secret shopper study of 49 websites selling GLP-1 receptor agonists found more than 90% issued a prescription, often without bloodwork, photo verification, or clinician interaction.

Shipra Patel, MD, MS, discusses her recent study highlighting best practices for phase 1 and 2 obesity trials to avoid attrition and loss of data.

Greater BMI reduction with semaglutide in adolescents with severe obesity was tied to improved triglycerides, TG/HDL ratio, and HbA1c

New data from ENDO 2026 reflect the accompanying reductions in HbA1c, lipids, and other major biomarkers in patients treated with GLP-1 RAs.

Stay updated with the latest healthcare breakthroughs, including data from ADA Scientific Sessions, a new CKM syndrome guideline, and more.

Fonseca discusses substantially lower persistence and adherence with GLP-1s in real-world practice, highlighting methods for clinicians to address this.

Shaminie Athinarayanan, PhD, discusses her recent study investigating the role of carbohydrate reduction in patients with obesity currently going through menopause.

Elecoglipron 75 mg produced 10.5% body weight reduction at 26 weeks in VISTA and a 1.9% HbA1c reduction at 26 weeks in SOLSTICE.

In the phase 2 SLIMMER-UP-SWITCH trial, ecnoglutide delivered greater weight loss and waist circumference reduction than semaglutide at 20 weeks in adults with obesity in China.

Across a trio of phase 3 trials, CagriSema delivered superior HbA1c reduction and weight loss versus semaglutide in adults with type 2 diabetes

Vivian Fonseca, MD, explains data showing nearly half of patients with T2D discontinued GLP-1 therapy within 1 year, reducing their likelihood of achieving weight loss and HbA1c goals.

Timothy Garvey, MD, discusses petrelintide’s efficacy in patients with overweight and obesity, as well as its comparably low incidence of gastrointestinal effects.

Carel le Roux, PhD, discusses the full results from SYNCHRONIZE-1, a trial investigating Boehringer Ingelheim’s dual GLP-1/glucagon agonist.

In a post-hoc analysis of ATTAIN-1 and ATTAIN-2, the highest dose of orforglipron delivered meaningful weight loss across all menopause stages.

Buse discusses phase VESPER results, berobenatide's weight loss potential, and expectations for the upcoming phase 3 program

Eli Lilly’s investigative GLP-1/GIP/glucagon triple agonist has demonstrated its efficacy in reducing several major factors of obesity versus placebo.

Eli Lilly’s investigative GLP-1/GIP/glucagon triple agonist has outperformed placebo in patients with poorly-controlled T2D.

VESPER-1 and VESPER-3 findings highlight the potential of berobenatide, an investigational ultra-long-acting GLP-1 RA, for overweight or obesity with or without type 2 diabetes.

A post-hoc analysis of the STEP UP trial found that semaglutide 7.2 mg and 2.4 mg were linked to eGFR increases in adults with obesity who did not have diabetes.

ACCESS phase 2b data show aleniglipron 120 mg produced 11.3% placebo-adjusted weight loss at 36 weeks, with continued reductions in the OLE.